Who
Peter Blume-Jensen
President and CEO
Company insider
Files Form 4 as: President and CEO, Acrivon Therapeutics.
In numbers
- Trades disclosed
- 47
- Buys
- 1
- Sells
- 2
- Bought
- $164K
- Sold
- $65K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Nov 2022
- Last trade
- 25 Aug 2026
- Last filed
- 27 Aug 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Aug 2026filed 27 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K14,036 at $2.21 | filing |
| 25 Aug 2026filed 27 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K14,036 at $2.21 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,4701,229 at $2.01 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $973484 at $2.01 | filing |
| 21 May 2026filed 26 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $25K13,729 at $1.79 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —180,095 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —72,706 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —180,095 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —72,706 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,4061,253 at $1.92 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $941490 at $1.92 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,4061,253 at $1.92 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $941490 at $1.92 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —417,210 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,495 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —417,210 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,495 at $0.00 | filing |
| 21 Feb 2026filed 24 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $22K14,265 at $1.53 | filing |
| 21 Feb 2026filed 24 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $22K14,265 at $1.53 | filing |
| 14 Feb 2026filed 18 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,1221,302 at $1.63 | filing |
News
No headline names them, or the companies they trade most, lately.